title: A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders.
abstract: BACKGROUND
  Nonadherence to prescribed medication regimens is a substantial barrier to the pharmacological management of alcohol use disorders. The availability of low-cost, sustainable interventions that maximize medication adherence would likely lead to improved treatment outcomes. Mobile health (mHealth) technologies are increasingly being adopted as a method of delivering behavioral health interventions and represent a promising tool for adherence interventions. We are evaluating a cell-phone-based intervention called AGATE that seeks to enhance adherence with regular text-messaging.
  
  
  METHODS
  A randomized controlled effectiveness trial in the context of an eight-week open label naltrexone efficacy trial delivered in a naturalistic clinical setting. Treatment-seeking heavy drinkers (N = 105) are currently being recruited and randomly assigned to the AGATE intervention or a control condition. Daily measures of alcohol use and medication side effects are being recorded via cell phone in both conditions. Additionally, participants randomized to the AGATE condition receive medication reminders via SMS text message according to a schedule that adjusts according to their level of adherence.
  
  
  CONCLUSIONS
  Results from this trial will provide initial information about the feasibility and efficacy of mHealth interventions for improving adherence to alcohol pharmacotherapies.
  
  
  BACKGROUND
  NCT01349985.
authors.affiliation: Talaria, Inc, 1121 34th Ave, Seattle, WA 98122, USA. sstoner@talariainc.com
authors.forename: Susan A
authors.initials: SA
authors.lastname: Stoner
authors.forename: Christian S
authors.initials: CS
authors.lastname: Hendershot
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000188:drug therapy*; D040421:Cell Phone; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017216:Telemedicine / Q000379:methods / Q000458:organization & administration*
chemical_list: D009292:Narcotic Antagonists; D009271:Naltrexone